💡 60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoff Dow discusses the company’s mission to tackle infectious diseases with unmet medical needs — and how its FDA-approved malaria drug ARAKODA® (tafenoquine) could soon transform treatment for babesiosis, a growing tick-borne disease with no approved therapies.🚀 Key Highlights:• FDA Breakthrough Therapy Designation request submitted for tafenoquine in babesiosis (Oct 2025)• First patient cured of relapsing babesiosis using tafenoquine-based regimen• Three clinical trials underway, with data expected in 2026 to support a supplementary NDA• $245M peak U.S. market potential and ~$1.1B cumulative revenue opportunity through 2035• Commercial launch underway for ARAKODA® in malaria prevention as travel rebounds📈 Why This Matters for Investors:60 Degrees Pharmaceuticals is one of the smallest Nasdaq-listed biotechs with an FDA-approved product — and it’s pursuing a capital-efficient expansion into a large, underserved infectious disease market. With strong early efficacy signals, a clear regulatory roadmap, and increasing awareness of babesiosis nationwide, SXTP offers investors exposure to a high-upside, low-cost clinical advancement story.🧬 About the Company:60 Degrees Pharmaceuticals (Nasdaq: SXTP) develops and commercializes therapeutics for vector-borne diseases. Its lead product, ARAKODA®, is FDA-approved for malaria prevention and is being advanced into new indications including babesiosis.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!60 Degrees Pharmaceuticals is a client of RedChip. To learn more about SXTP and to read our full disclosure, visit: SXTPinfo.com.#SXTP #BiotechStocks #FDAApproval #PharmaInvesting #MicroCapStocks #InfectiousDiseases #Babesiosis #MalariaPrevention #HealthcareInnovation #Investors

🔋 Bimergen Energy (OTCQB: BESS) is emerging as a major player in the booming U.S. battery energy storage sector—and CFO Bob Brilon shares how the company is executing on a 2.0 GW pipeline backed by $250 million in equity commitments.With 2GW of BESS assets and a capital-efficient model designed to avoid shareholder dilution, Bimergen is positioned to become a cornerstone in the next generation of U.S. energy infrastructure.🗓️ Construction begins late 2025, operations expected in 2026.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bimergen Energy is a client of RedChip. To learn more about BESS and to read our full disclosure, visit: Bimergeninfo.com.#BESS #BatteryStorage #MicroCapStocks #EnergyStorage #AIInfrastructure #CleanEnergy #Bimergen #Investing #StockMarket #EnergyTransition

Mark White, CEO of Nexalin Technology (Nasdaq: NXL), joins us to discuss how Nexalin aims to simplify and make mental health care more accessible with its at-home “Halo” headset and a digital, physician-monitored model. We cover the latest peer-reviewed study results referenced by the company, the plan for U.S. and international pathways, and what investors should watch next.🎯 What you’ll learn• Nexalin’s vision for easy, drug-free, non-invasive support delivered at home• How the “Halo” headset fits into a virtual care workflow (physician-monitored)• Key takeaways from the company-referenced, peer-reviewed Alzheimer’s study• Commercial model: device + subscription (“razor/razor-blade” economics)• Near-term focus areas: mood/anxiety/sleep, TBI/PTSD, and early dementia• How management thinks about FDA strategy and global expansion🧠 Study reference (as discussed)• Nexalin references a peer-reviewed publication reporting statistically significant cognitive improvements and fMRI-observed connectivity changes in a mild Alzheimer’s cohort using a 40-Hz, 15 mA protocol, with no adverse events reported during the treatment period. 💼 Business model• Clinical setting: device placement with physicians; recurring revenue via single-use disposables/treatments• At-home: headset prescribed/ordered by a physician; subscription to access and remote monitoring via app/cloud• Goal: scale through a digital ecosystem that integrates diagnosis, treatment access, and physician oversight🔎 For investors• Thesis: simplified access, physician-monitored use at home, and recurring revenue economics could unlock a capital-efficient growth path if regulatory and clinical milestones are achieved.• Watchlist catalysts: additional study readouts, regulatory interactions/decisions, progress on U.S. pathway, international indication expansions, commercial pilots/rollouts, and updates on subscription adoption and reimbursement discussions.🔔 Drop your questions for Mark in the comments for future Q&A!Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Nexalin is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: NXLinfo.com.#Nexalin #NXL #MedTech #DigitalHealth #BrainHealth #Investing #Neurotechnology #Alzheimers #MentalHealth #AtHomeCare

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefiningoncology drug development through artificial intelligence. Its proprietary RADR® platform leveragesover 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patienttargeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%,respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC innever-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressiveB-cell lymphomas. The company also advances CNS oncology programs via its subsidiary StarlightTherapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with globalpartners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanningJohns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value throughprecision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit LTRNinfo.com to learn more.

Foremost Clean Energy (Nasdaq: FMST) is a rapidly growing North American uranium exploration holding an option to earn up to a 70% interest in 10 underexplored properties from Denison Mines. The portfolio spans over 330,000 acres within a prospective area of the Athabasca Basin surrounded by high-grade deposits. Driven by the resurgent Nuclear Renaissance, Foremost is dedicated to realizing the full potential of its projects, actively exploring in collaboration with Denison. Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/fmst to learn more.

Phoenix Motor (OTC: PEVMD) is a pioneer and emerging leader in the electric vehicle (“EV”) industry, designing, building, and integrating electric drive systems and manufacturing heavy-duty transit buses and medium- and light- duty commercial EVs. Phoenix operates two primary brands, PhoenixEV, focused on commercial products including heavy and medium duty EVs (transit buses, shuttle buses, school buses and delivery trucks, among others) and EdisonFuture, which intends to serve international markets, particularly Latin America and Caribbeans region.Phoenix is capitalizing on a robust market opportunity backed by significant federal and state regulatory mandates. With a commanding market share in the transit bus segment and a strategic presence in medium-duty vehicles, Phoenix has established a competitive edge through superior product quality and total cost of ownership. The Company has a base of high-profile customers and boasts a strong order backlog, evidencing substantial market demand, with contracted orders and letters of intent for approximately 250+ units representing $200M in potential revenue. Learn more at phoenixev.ai.PhoenixEV is a client of RedChip. Visit www.redchip.com/stocks/PEVMD to learn more.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60 Degrees Pharmaceuticals is a client of RedChip. Visit www.redchip.com/stocks/SXTP to learn more.

Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.Aptevo Therapeutics is a client of RedChip. Visit APVOinfo.com to learn more.

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.Calidi Biotherapeutics is a client of RedChip. Visit www.redchip.com/stocks/cldi to learn more.

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefining oncology drug development through artificial intelligence. Its proprietary RADR® platform leverages over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%, respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC in never-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressive B-cell lymphomas. The company also advances CNS oncology programs via its subsidiary Starlight Therapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with global partners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanning Johns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value through precision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit RedChip.com to learn more.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is strategically prioritizing metastatic breast cancer, where (Z)-endoxifen has shown encouraging clinical activity, favorable tolerability, and potential to address endocrine resistance through dual targeting of ERα and PKCβ1. With multiple Phase 2 trials completed, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Atossa Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/atos to learn more.

Processa Pharmaceuticals (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies, resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa's strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.Processa is a client of RedChip. Visit www.redchip.com/stocks/pcsa to learn more.

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or “over-expressor”) levels.Greenwich LifeSciences is a client of RedChip. Visit RedChip.com/stocks/GLSI to learn more.

Fathom Holdings Inc. (Nasdaq: FTHM) is a technology-driven real estate services platform revolutionizing the traditional brokerage model. Through its innovative flat-fee commission structure, proprietary technology, and integrated offerings—spanning residential brokerage, mortgage, title, and SaaS—Fathom enables agents to maximize their earnings while delivering superior scalability and efficiency. With operations across 43 states and a rapidly growing network of over 14,700 agents, Fathom is well-positioned to capitalize on an improving housing market and expand its disruptive, high-margin approach to real estate services.Visit RedChip.com to learn more.

ASP Isotopes is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing.ASP Isotopes is a client of RedChip. Visit www.redchip.com/stocks/aspi to learn more.

Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.Enlivex Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/enlv to learn more.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.Visit RedChip.com to learn more.

Foremost Clean Energy Ltd. (Nasdaq: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/FMST to learn more.

FatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity. The company develops and markets enterprise-class software solutions—including Software-Defined Wide Area Networking (SD-WAN), Secure Access Service Edge (SASE), and Network Monitoring Services (NMS)—that enable customers to unify, secure, and optimize their digital infrastructure across cloud, hybrid, and on-premise environments.FatPipe serves over 2,500 end-user customers worldwide across sectors such as government, healthcare, finance, education, and retail, with its largest customer bases in the U.S. and India. The company’s patented technology allows for intelligent traffic failover, enhanced security, simplified network management, and deep observability—all delivered through a flexible, subscription-based model. For the fiscal year ended March 31, 2024, FatPipe generated $17.9 million in revenue and $4.4 million in net income—reflecting a strong 24.4% net margin.FatPipe is a client of RedChip. Visit RedChip.com to learn more.

BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more.